A prognostic model for lung adenocarcinoma patient survival with a focus on four miRNAs

Li,Xianqiu; An,Zhaoling; Li,Peihui; Liu,Haihua

doi:10.3892/ol.2017.6481

A prognostic model for lung adenocarcinoma patient survival with a focus on four miRNAs

Authors:
- Xianqiu Li
- Zhaoling An
- Peihui Li
- Haihua Liu
View Affiliations

Affiliations: Department of Pharmacy, Weifang People's Hospital,Weifang, Shandong 261041, P.R. China
Published online on: June 27, 2017 https://doi.org/10.3892/ol.2017.6481
Pages: 2991-2995
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

There is currently no effective biomarker for determining the survival of patients with lung adenocarcinoma. The purpose of the present study was to construct a prognostic survival model using microRNA (miRNA) expression data from patients with lung adenocarcinoma. miRNA data were obtained from The Cancer Genome Atlas, and patients with lung adenocarcinoma were divided into either the training or validation set based on the random allocation principle. The prognostic model focusing on miRNA was constructed, and patients were divided into high-risk or low-risk groups as per the scores, to assess their survival time. The 5-year survival rate from the subgroups within the high- and low-risk groups was assessed. P-values of the prognostic model in the total population, the training set and validation set were 0.0017, 0.01986 and 0.02773, respectively, indicating that the survival time of the lung adenocarcinoma high-risk group was less than that of the low-risk group. Thus, the model had a good assessment effectiveness for the untreated group (P=0.00088) and the Caucasian patient group (P=0.00043). In addition, the model had the best prediction effect for the 5-year survival rate of the Caucasian patient group (AUC=0.629). In conclusion, the prognostic model developed in the present study can be used as an independent prognostic model for patients with lung adenocarcinoma.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
3	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
4	Herbst RS, Heymach JV and Lippman SM: Lung cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
5	Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, et al: Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 150:1107–1120. 2012. View Article : Google Scholar : PubMed/NCBI
6	Peng F, Li H, Ning Z, Yang Z, Li H, Wang Y, Chen F and Wu Y: CD147 and prostate cancer: a systematic review and meta-analysis. PLoS One. 11:e0163672016. View Article : Google Scholar
7	Toh CK, Gao F, Lim WT, Leong SS, Fong KW, Yap SP, Hsu AA, Eng P, Koong HN, Thirugnanam A and Tan EH: Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol. 24:2245–2251. 2006. View Article : Google Scholar : PubMed/NCBI
8	Subramanian J and Govindan R: Lung cancer in never smokers: a review. J Clin Oncol. 25:561–570. 2007. View Article : Google Scholar : PubMed/NCBI
9	Gavelli G and Giampalma E: Sensitivity and specificity of chest X-ray screening for lung cancer: review article. Cancer. 89 Suppl:2453–2456. 2000. View Article : Google Scholar : PubMed/NCBI
10	Hayes J, Peruzzi PP and Lawler S: MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
11	Zhao Z, Li S, Song E and Liu S: The roles of ncRNAs and histone-modifiers in regulating breast cancer stem cells. Protein Cell. 7:89–99. 2016. View Article : Google Scholar : PubMed/NCBI
12	OKelly F, Marignol L, Meunier A, Lynch TH, Perry AS and Hollywood D: MicroRNAs as putative mediators of treatment response in prostate cancer. Nat Rev Urol. 9:397–407. 2012. View Article : Google Scholar : PubMed/NCBI
13	Zhou L, Zhao LC, Jiang N, Wang XL, Zhou XN, Luo XL and Ren J: MicroRNA miR-590-5p inhibits breast cancer cell stemness and metastasis by targeting SOX2. Eur Rev Med Pharmacol Sci. 21:87–94. 2017.PubMed/NCBI
14	Feng Y, Liu J, Kang Y, He Y, Liang B, Yang P and Yu Z: miR-19a acts as an oncogenic microRNA and is up-regulated in bladder cancer. J Exp Clin Cancer Res. 33:672014. View Article : Google Scholar : PubMed/NCBI
15	Robinson MD, McCarthy DJ and Smyth GK: edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 26:139–140. 2010. View Article : Google Scholar : PubMed/NCBI
16	Posada D and Buckley TR: Model selection and model averaging in phylogenetics: advantages of Akaike information criterion and Bayesian approaches over likelihood ratio tests. Syst Biol. 53:793–808. 2004. View Article : Google Scholar : PubMed/NCBI
17	Huang W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
18	Chang L, Guo F, Huo B, Lv Y, Wang Y and Liu W: Expression and clinical significance of the microRNA-200 family in gastric cancer. Oncol Lett. 9:2317–2324. 2015.PubMed/NCBI
19	Liu J, Pang Y, Wang H, Li Y, Sun X, Xu F, Ren H and Liu D: miR-101 inhibits the proliferation and migration of breast cancer cells via downregulating the expression of DNA methyltransferase 3a. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 32:299–303. 2016.(In Chinese). PubMed/NCBI
20	Fan P, Liu L, Yin Y, Zhao Z, Zhang Y, Amponsah PS, Xiao X, Bauer N, Abukiwan A, Nwaeburu CC, et al: MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer. Cancer Lett. 373:130–137. 2016. View Article : Google Scholar : PubMed/NCBI
21	Cao K, Li J, Zhao Y, Wang Q, Zeng Q, He S, Yu L, Zhou J and Cao P: miR-101 inhibiting cell proliferation, migration and invasion in hepatocellular carcinoma through downregulating Girdin. Mol Cell. 39:96–102. 2016. View Article : Google Scholar
22	Zhao Z, Li R, Sha S, Wang Q, Mao W and Liu T: Targeting HER3 with miR-450b-3p suppresses breast cancer cells proliferation. Cancer Biol Ther. 15:1404–1412. 2014. View Article : Google Scholar : PubMed/NCBI